NCT03583138

HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)

Project STRIDE2 - Seek/Test/Retain: PLWHA and Opioid Users in Washington, DC

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 159 (actual)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are dependent on opioids. This study is funded by the National Institute on Drug Abuse (R01DA030768, Altice, PI; Taxman \& Lawson, Co-PIs) and is being conducted by George Mason University, Yale University, and Howard University.

Detailed description

STRIDE2 will assist in identifying and monitoring individuals' HIV risk behaviors and provide resources to seek treatment for their HIV care and substance use. The goal of STRIDE2 is to examine if there are differences in HIV, drug use, and other outcomes between individuals receiving treatment versus individuals actively using, not actively using and not in treatment, and individuals on Methadone, Suboxone, or in some other treatment.

Conditions

• Human Immunodeficiency Virus
• Acquired Immunodeficiency Syndrome
• Opiate Addiction
• Drug Dependence

Interventions

Type	Name	Description
DRUG	buprenorphine	To provide buprenorphine for 12 months for those who are interested in receiving it.

Timeline

• Start date: 2014-06-23
• Primary completion: 2015-12-15
• Completion: 2017-06-30
• First posted: 2018-07-11
• Last updated: 2020-05-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study